ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's ...

ImmunityBio, Inc. (NASDAQ: IBRX) is among the 12 Best Performing Stocks in February.

mRNA-1345, a lipid nanoparticle encapsulated messenger RNA (mRNA)-based vaccine, was well tolerated and immunogenic in solid organ transplant recipients, inducing neutralizing antibodies against ...

Researchers at the National University of Singapore (NUS) have identified a protein called tyrosine phosphatase 1B (PTP1B) as a potential "switch" that can modulate a type of cancer cell death known ...

Researchers at the National University of Singapore (NUS) have identified a protein called tyrosine phosphatase 1B (PTP1B) as ...

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2026 / New to The Street, the nationally syndicated, long-form ...

Immunogenic cell death (ICD) is emerging as a critical mechanism that bridges local cancer therapy with systemic immune responses. This study provides a quantitative framework that integrates ICD, ...

Atezolizumab combined with R-GemOx shows favorable safety and efficacy in relapsed/refractory DLBCL, especially in transformed FL cases. The study reported a 59% overall response rate and a 33% ...

LAWRENCEVILLE, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company focused on developing non-viral DNA-mediated immunotherapy and evaluating an adaptation of ...

THURSDAY, Feb. 6, 2025 (HealthDay News) -- Neoantigen-targeting personalized cancer vaccines (PCVs) are highly immunogenic in high-risk clear cell renal cell carcinoma (RCC) and can target key driver ...

Cancer immunotherapy has shown significant potential in treating several malignancies by stimulating the host immune system to recognize and attack cancer cells. Immunogenic cell death (ICD) can ...